Fig. 5.

JAK1 mutations, mutation load, and CMS1 are associated with a good patient outcome. a Among 175 patients with MSI+ CRC from Norwegian series I and II and the VICTOR trial, tumors with JAK1 frameshift indels were associated with a better 5-year overall survival rate (94%) than wild-type tumors (75%; P value from Wald’s test). b Among the 33 exome-sequenced tumors in Norwegian series I, tumors with a mutation load above the median number of mutations were associated with a better 5-year relapse-free survival rate (100%) than tumors with a low mutation load (63%; P value from the log-rank test). c Among 119 patients in Norwegian series I and a publicly available dataset (GEO accession number GSE39582), patients in CMS1 had a significantly better 5-year relapse-free survival rate (81%) than patients in CMS2-4 (57%, P value from Wald’s test)